Simple

Micron’s “peel & stick” microneedle patch is applied simply by pressing it against the skin, like a BAND-AID®. This simple and minimally-invasive approach eliminates pain and fear associated with injections and allows for self-administration with little to no training.

Peel

Peel patch from protective cap

&

Stick

Stick patch to skin

Targets Skin

Upon application of the patch to the skin, microneedles painlessly penetrate the upper layers of skin and dissolve rapidly, thereby releasing their drug(s) or vaccine(s). After a few minutes, the patch is removed from the skin.  Because the microneedles dissolve in the skin, there is no sharps waste.

Patch is applied to skin

Microneedles disolve and release their active

Sharps-free backing is removed and discarded

Improves Efficacy

By delivering medicines into the outer layers of skin, the microneedle patch targets dermal immune system cells, which has been shown to elicit enhanced immune responses and dose sparing when vaccines are delivered by microneedle patch.  Also, the microneedle patch targets blood capillaries just below the epidermis, which has been shown to enhance the pharmacokinetic and pharmacodynamics effects of certain drugs.

Painless

Because the microneedles penetrate only the upper layers of skin, they do not reach the deeper nerve endings, which makes Micron’s microneedle patch painless.

Happy Baby at the Doctor

Thermostable

Micron’s proprietary formulation and manufacturing processes have been shown to provide thermostability to encapsulated drugs and other actives, thereby allowing for reduction and sometimes elimination of the cold chain.

Versatile

Microneedle patches are suitable for a wide range of active (therapeutics and vaccines) and inactive compounds including small molecule, nucleic acids, peptides, proteins, and micro/nano-particles.

Micron develops pharmaceutical products, based on its microneedle patch technology, that are designed to provide enhanced protective (vaccine) and therapeutic (drugs) effects, superior patient compliance, and simplified administration, distribution, and storage logistics.

News

Micron Biomedical Appoints Brian Bernick, MD as Chairman of Its Board of Directors

ATLANTA, Aug. 9, 2023 /PRNewswire/ — Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the administration, transport and storage of drugs and vaccines, today announced the appointment of drug delivery and healthcare innovation veteran, Brian Bernick, MD, as Chairman of the company’s Board of Directors. “Dr. Brian Bernick has a long-standing record of…

Micron Biomedical Announces Positive Measles and Rubella Vaccination Results from First Clinical Trial of Microarray Injection-Free Vaccine Delivery in Children

Successful Phase 1/2 study is the first clinical trial of any microarray technology in pediatric populations as the need for a pain-free, logistically simplified vaccine delivery option grows worldwide. ATLANTA, May 17, 2023 /PRNewswire/ — Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the administration, transport, and storage…

Micron Biomedical Extends Series A to $17 Million to Bring Needle-Free Drugs and Vaccines to Market

$3 Million Series A Extension Continues Validation of Company’s Commercial Strategy. ATLANTA, May 10, 2023 /PRNewswire/ — Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that are simplifying and advancing the delivery and administration of drugs and vaccines, today announced it has secured an additional $3 million investment from J2 Ventures, bringing…